CLOROX CO /DE/

Regulatory Filings • Sep 10, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Field: Rule-Page

Field: /Rule-Page

FORM 8-K

CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 10, 2024

THE CLOROX COMPANY (Exact name of registrant as specified in its charter)

Field: Rule-Page

Field: /Rule-Page

Delaware	1-07151	31-0595760
(State
or other jurisdiction of	(Commission
File Number)	(I.R.S.
Employer
incorporation)		Identification
No.)

1221 Broadway , Oakland , California 94612-1888 (Address of principal executive offices) (Zip code)

( 510 ) 271-7000 (Registrant's telephone number, including area code)

Not applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

| [
] | Written
communications pursuant to Rule 425 Under the Securities Act (17 CFR 230.425) |
| --- | --- |
| [
] | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [
] | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [
] | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title
of each class | Trading Symbol(s) | Name
of each exchange on which registered |
| --- | --- | --- |
| Common
Stock - $1.00 par value | CLX | New
York Stock Exchange |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1; Options: NewSection; Value: 1

Field: Sequence; Type: Arabic; Name: PageNo 1 Field: /Sequence

Field: /Page

Item 7.01 Regulation FD Disclosure

On September 10, 2024, The Clorox Company issued a press release announcing the completion of the divestiture of its Better Health Vitamins, Minerals and Supplements business. The full text of the press release related to the sale is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

See the Exhibit Index below.

EXHIBIT INDEX

Exhibit	Description
99.1	Press
Release dated September 10, 2024 of The Clorox Company
104	Cover
Page Interactive Data File (embedded within the Inline XBRL document)

Field: Page; Sequence: 2; Value: 1

Field: Sequence; Type: Arabic; Name: PageNo 2 Field: /Sequence

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| /s/
Angela Hilt |
| --- |
| Angela
Hilt |
| Executive
Vice President – Chief Legal Officer and Corporate Secretary |

Field: Page; Sequence: 3; Options: Last

Field: Sequence; Type: Arabic; Name: PageNo 3 Field: /Sequence

Field: /Page

Field: Set; Name: xdx; ID: xdx_08B_extensions eJxFjd2KwjAQhZ+g7zDkumhat4i92y21yFaRIuJt3E6XYJspk/j3SPuWG9MLh4HhcM43R4hYVLTWPTKcvpoaDjiMvXIIDXbIaH7QJ4rNdw7+NvirrWNlXJAVBSSbpYuzlyFw0xbbHORqnsh5+gEyy7MlfG5F9PILMp1u0TitelCmhT3TyBqd4uf04aAeZGh4hoIjstVkckhmcrL/IJVJCju6qTvxxUJdFyKKw0SiYrqOPlU+HJoXCWWPg6+zE/3e6B85IkZz